Before selecting cloud-based Veeva CRM for 500+
users worldwide, Actelion Ltd. had been operating 10 different client/server
salesforce automation (SFA) systems - all from various vendors - throughout its
operations around the world. This technology labyrinth was increasingly
expensive to maintain, difficult to update, functionally deficient, and
disconnected from region to region. Actelion needed an innovative solution that
would align sales globally. So, managers from the company's 29 regions
established selection criteria, followed by an exhaustive RFP process involving
five vendors. Only Veeva CRM, with its rich capabilities for integrating
diverse selling teams, streamlined sales reporting, and rich iPad application
met all of the company's needs.
"Our search for a single, global CRM solution was
driven by today's increasingly challenging business environment. In order to compete, we need the tools that
will enable us to gain a better understanding of our customer's needs and be
more responsive," said Actelion's Head of Global Commercial Excellence
Christoph Schmidt, PhD. "Veeva offered industry-specific functionality for all
different user groups - from key opinion leader managers to key account execs
and field reps - around the world, all integrated within a single solution."
Schmidt continued, "Global deployment of Veeva
CRM will ensure quality and consistency across countries, enable us to share
best practices worldwide, and allow our organisation to fully benefit from the
economies of scale of a global cloud deployment."
"After fast and successful pilot projects in US,
Canada, China, and Australia, Actelion decided to deploy Veeva CRM globally."
The remaining regions - including all European territories - are expected to be
live with Veeva CRM by the end of 2012. Actelion executives cited Veeva CRM's
proven track record with over 30,000 satisfied users globally, role specific
capabilities, and trailblazing cloud-based technology as deciding factors in
the selection process.
"The cloud enables many business and operational
benefits including faster deployment, greater flexibility to enable quick
changes, and cost effectiveness," said Schmidt. "And, with Veeva, we benefit
from free, regular application updates so that our field force is always up to
date. The upgrades are transparent, too, so they don't cause any disruption to
their work allowing us to spearhead technological advancements within the
organisation very quickly. This is a huge advantage."
Actelion has also started deploying iRep - the
first integrated CRM and CLM cloud-based solution designed specifically for the
iPad. iRep's "built in" closed loop
marketing seamlessly links customer data with interactive content allowing for
highly personalised interactions and automatic capture of call activity and
physician insight. The result is simply
a better user experience and higher quality customer interactions, without the
hassle and cost of multiple applications.
"We needed a solution that could leverage the
Apple iPad, but Veeva's iRep also offered us the unique ability to integrate
both CRM and CLM applications seamlessly. We knew that this would empower our
field force with the tools to better respond to customer needs -enabling them
to work faster, more efficiently and with greater impact," concluded Schmidt.
For more information,
visit
www.veevasystems.com.
About Actelion Ltd.
Actelion Ltd
is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,500 employees focus on
the discovery, development and marketing of innovative drugs for significant
unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange
(ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market
Index SMI®)
.
About Veeva CRM
The Veeva CRM suite of applications is the life
sciences industry's top cloud-based CRM solution. Veeva CRM offers rich
capabilities that meet the unique needs of various pharmaceutical and biotech
commercial teams. The complete Veeva CRM suite gives customers the mobility and
reporting solutions needed to drive user adoption and sales effectiveness.
About Veeva Systems
Veeva Systems is the
leader in cloud-based business solutions for the global life sciences industry.
Committed to innovation, product excellence, and customer success, Veeva has
over 100 customers, ranging from the world's largest pharmaceutical companies
to emerging biotechs. Founded in 2007, Veeva is a privately held company
headquartered in the San Francisco Bay Area, with offices in Philadelphia,
Barcelona, Budapest, Paris, Beijing, Shanghai, and Tokyo.